AVLN Stock News & Catalysts

FEATURED

Avalyn to Present at Upcoming Investor Conferences

BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory

Summary

Nov 3, 2026, 8:00 AM ·Globe Newswire

RECENT

Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile

Results validate Avalyn’s approach of delivering established antifibrotic medicines directly to the lungs to maximize local exposure while limiting systemic exposure and improving tolerability Findings support

Sep 21, 2026, 9:00 AM ·Globe Newswire

Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors

BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN) ("Avalyn" or the "Company"), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the

Sep 16, 2026, 4:01 PM ·Globe Newswire

Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory

Sep 8, 2026, 8:00 AM ·Globe Newswire

Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis

In silico modeling predicts robust AP01 distribution in healthy and fibrotic lungs, even in severe disease Patient survey findings suggest that clear communication, transparent discussions of potential benefits and

Sep 8, 2026, 8:00 AM ·Globe Newswire

Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026

BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory

Aug 24, 2026, 4:01 PM ·Globe Newswire

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted for presentation at the European Respiratory Society (ERS) Congress,

Aug 12, 2026, 8:00 AM ·Globe Newswire

Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis

BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN) (Avalyn or the Company), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of

Jun 17, 2026, 8:00 AM ·Globe Newswire

Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights

On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PPF) in mid-2026, with newly presented long term open-label extension clinical data that support favorable tolerability

Jun 3, 2026, 7:00 AM ·Globe Newswire

Avalyn to Participate in the Jefferies Global Healthcare Conference

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory

May 27, 2026, 8:00 AM ·Globe Newswire

Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory

May 21, 2026, 8:00 AM ·Globe Newswire

Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory

May 5, 2026, 4:01 PM ·Globe Newswire

Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics' Acquisition by UCB

Two River, LLC ("Two River") and Vida Ventures ("Vida"), both part of the Bellco Health ecosystem, today acknowledged the announced acquisition of Candid Therapeutics ("Candid"), a privately held clinical-stage

May 3, 2026, 8:00 PM ·Business Wire

Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory

May 1, 2026, 4:01 PM ·Globe Newswire

Avalyn Announces Pricing of Upsized Initial Public Offering

BOSTON, April 29, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN) ("Avalyn"), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare

Apr 29, 2026, 9:00 PM ·Globe Newswire

Avalyn Pharma Inc. Common Stock AVLN · News